Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-50505
Hofer, S; Elandt, K; Greil, R; Hottinger, A F; Huber, U; Lemke, D; Marosi, C; Ochsenbein, A; Pichler, J; Roelcke, U; Weder, P; Zander, T; Wick, W; Weller, M (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncologica, 50(5):630-635.
PDF - Registered users only
Our data reveal valuable palliation with preservation of KPS and an option for steroid withdrawal in patients treated with BEV, supporting the role of this therapy in late-stage disease.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|DDC:||610 Medicine & health|
|Deposited On:||14 Nov 2011 14:37|
|Last Modified:||27 Nov 2013 22:40|
|Publisher:||Taylor & Francis|
|Citations:||Web of Science®. Times cited: 18|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page